{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:29:42Z","timestamp":1770413382591,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Harmannus Ehrhardt Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40262-025-01601-5","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T15:37:00Z","timestamp":1765467420000},"page":"277-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics of Total and Protein-Unbound Prednisolone in Children with Immune-Mediated and Systemic Inflammatory Diseases"],"prefix":"10.1007","volume":"65","author":[{"given":"Julia E.","family":"M\u00f6hlmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline A.","family":"Lindemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H. A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs","family":"van Luin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjen M.","family":"Punt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solaiman","family":"Ezzafzafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelia H. M.","family":"de Vries Schultink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"2","key":"1601_CR1","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/ijms20020444","volume":"20","author":"G Ferrara","year":"2019","unstructured":"Ferrara G, Petrillo MG, Giani T, Marrani E, Filippeschi C, Oranges T, et al. Clinical use and molecular action of corticosteroids in the pediatric age. Int J Mol Sci. 2019;20(2):444.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1601_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40262-018-0639-4","volume":"57","author":"LJJ Derijks","year":"2018","unstructured":"Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57(9):1075\u2013106.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1601_CR3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3748\/wjg.v17.i9.1095","volume":"17","author":"S De Iudicibus","year":"2011","unstructured":"De Iudicibus S, Franca R, Martelossi S, Ventura A, Decorti G. Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol. 2011;17(9):1095\u2013108.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"1601_CR4","doi-asserted-by":"publisher","first-page":"600.e1","DOI":"10.1016\/j.jtct.2022.06.008","volume":"28","author":"AB Verbeek","year":"2022","unstructured":"Verbeek AB, Jansen SA, von Asmuth EGJ, Lankester AC, Bresters D, Bierings M, et al. Clinical features, treatment, and outcome of pediatric steroid refractory acute graft-versus-host disease: a multicenter study. Transplant Cell Ther. 2022;28(9):600.e1-600.e9.","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"1601_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood.2022015734","volume":"141","author":"AGS van Halteren","year":"2023","unstructured":"van Halteren AGS, Suwandi JS, Tuit S, Borst J, Laban S, Tsonaka R, et al. A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease. Blood. 2023;141(11):1277\u201392.","journal-title":"Blood"},{"issue":"2","key":"1601_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","volume":"20","author":"AK McDonough","year":"2008","unstructured":"McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20(2):131\u20137.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"1601_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, Keller F, Rasche FM, H\u00e4ussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61\u201398.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1601_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1055\/s-0042-108071","volume":"48","author":"EJ Meyer","year":"2016","unstructured":"Meyer EJ, Nenke MA, Rankin W, Lewis JG, Torpy DJ. Corticosteroid-Binding Globulin: a review of basic and clinical advances. Horm Metab Res. 2016;48(6):359\u201371.","journal-title":"Horm Metab Res"},{"key":"1601_CR9","unstructured":"DIAsource ImmunoAssays S.A. CBG-RIA-CT - KIP1809\u2014instructions for use. 2023 [cited 2025 Feb 4]. https:\/\/diasource.s3.eu-west-3.amazonaws.com\/website\/medias\/2023\/09\/kip1809-650314b0b9916.pdf?1694700720."},{"issue":"10","key":"1601_CR10","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1210\/jc.2001-011843","volume":"87","author":"JM Fernandez-Real","year":"2002","unstructured":"Fernandez-Real JM, Pugeat M, Grasa M, Broch M, Vendrell J, Brun J, et al. Serum corticosteroid-binding globulin concentration and insulin resistance syndrome: a population study. J Clin Endocrinol Metab. 2002;87(10):4686\u201390.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1601_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/cen.13969","volume":"91","author":"J Melin","year":"2019","unstructured":"Melin J, Hartung N, Parra-Guillen ZP, Whitaker MJ, Ross RJ, Kloft C. The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing. Clin Endocrinol (Oxf). 2019;91(1):33\u201340.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1601_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/clpt.1990.167","volume":"48","author":"MR Hill","year":"1990","unstructured":"Hill MR, Szefler SJ, Ball BD, Bartoszek M, Brenner AM. Monitoring glucocorticoid therapy: a pharmacokinetic approach. Clin Pharmacol Ther. 1990;48(4):390\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1601_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-2125.1984.tb02367.x","volume":"17","author":"G Gatti","year":"1984","unstructured":"Gatti G, Perucca E, Frigo GM, Notarangelo LD, Barberis L, Martini A. Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Br J Clin Pharmacol. 1984;17(4):423\u201331.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1601_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/adc.65.2.196","volume":"65","author":"PF Miller","year":"1990","unstructured":"Miller PF, Bowmer CJ, Wheeldon J, Brocklebank JT. Pharmacokinetics of prednisolone in children with nephrosis. Arch Dis Child. 1990;65(2):196\u2013200.","journal-title":"Arch Dis Child"},{"issue":"4","key":"1601_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/FTD.0b013e31825ee3f8","volume":"34","author":"I S\u00e6ves","year":"2012","unstructured":"S\u00e6ves I, Line PD, Bergan S. The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. Ther Drug Monit. 2012;34(4):452\u20139.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"1601_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1177\/00912700122012733","volume":"41","author":"MH Magee","year":"2001","unstructured":"Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol. 2001;41(11):1180\u201394.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1601_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/00007691-200408000-00011","volume":"26","author":"JM Potter","year":"2004","unstructured":"Potter JM, McWhinney BC, Sampson L, Hickman PE. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population. Ther Drug Monit. 2004;26(4):408\u201314.","journal-title":"Ther Drug Monit"},{"issue":"9","key":"1601_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40262-024-01419-7","volume":"63","author":"JE M\u00f6hlmann","year":"2024","unstructured":"M\u00f6hlmann JE, Ezzafzafi S, Lindemans CA, Jansen MHA, Nierkens S, Huitema ADR, et al. Pharmacokinetics and pharmacodynamics of systemic corticosteroids in autoimmune and inflammatory diseases: a review of current evidence. Clin Pharmacokinet. 2024;63(9):1251\u201370.","journal-title":"Clin Pharmacokinet"},{"issue":"1252","key":"1601_CR19","volume":"26","author":"JE M\u00f6hlmann","year":"2024","unstructured":"M\u00f6hlmann JE, van Luin M, Lentjes EGWM, Huitema ADR, Punt AM. Bioanalysis of protein-unbound prednisolone in serum using equilibrium dialysis followed by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;26(1252):124440.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"5309","key":"1601_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.276.5309.122","volume":"276","author":"GB West","year":"1997","unstructured":"West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276(5309):122\u20136.","journal-title":"Science"},{"issue":"1","key":"1601_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","volume":"24","author":"MM Rhodin","year":"2009","unstructured":"Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67\u201376.","journal-title":"Pediatr Nephrol"},{"issue":"92","key":"1601_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejps.2016.06.026","volume":"20","author":"KR Kn\u00f8sgaard","year":"2016","unstructured":"Kn\u00f8sgaard KR, Foster DJR, Kreilgaard M, Sverrisd\u00f3ttir E, Upton RN, van den Anker JN. Pharmacokinetic models of morphine and its metabolites in neonates: Systematic comparisons of models from the literature, and development of a new meta-model. Eur J Pharm Sci. 2016;20(92):117\u201330.","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"1601_CR23","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1111\/bcp.14738","volume":"87","author":"AL Nijstad","year":"2021","unstructured":"Nijstad AL, Nierkens S, Lindemans CA, Boelens JJ, Bierings M, Versluys AB, et al. Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients. Br J Clin Pharmacol. 2021;87(8):3218\u201326.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1601_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"6","key":"1601_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"AG Dosne","year":"2017","unstructured":"Dosne AG, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44(6):509\u201320.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1601_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"1601_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101(1):72\u20139.","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"1601_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bjh.17572","volume":"194","author":"SDT Sassen","year":"2021","unstructured":"Sassen SDT, Math\u00f4t RAA, Pieters R, de Haas V, Kaspers GJL, van den Bos C, et al. Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response. Br J Haematol. 2021;194(2):423\u201332.","journal-title":"Br J Haematol"},{"issue":"6","key":"1601_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00280-003-0602-3","volume":"51","author":"KB Petersen","year":"2003","unstructured":"Petersen KB, Jusko WJ, Rasmussen M, Schmiegelow K. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2003;51(6):465\u201373.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"1601_CR30","first-page":"632","volume":"17","author":"S Baron","year":"1988","unstructured":"Baron S, Raux Demay MC, Vasmant D, Bensman A. Pharmacokinetics of prednisolone in children. Study of a correlation with tolerability and therapeutic effect in nephrosis. Presse Med. 1988;17(13):632\u20135.","journal-title":"Presse Med"},{"issue":"7","key":"1601_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s002280050512","volume":"54","author":"C Faure","year":"1998","unstructured":"Faure C, Andr\u00e9 J, Pelatan C, Munck A, Giraud M, C\u00e8zard JP, et al. Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. Eur J Clin Pharmacol. 1998;54(7):555\u201360.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1601_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/BF00869822","volume":"4","author":"M Rostin","year":"1990","unstructured":"Rostin M, Barthe P, Houin G, Alvinerie M, Bouissou F. Pharmacokinetics of prednisolone in children with the nephrotic syndrome. Pediatr Nephrol. 1990;4(5):470\u20133.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"1601_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/FTD.0000000000000308","volume":"38","author":"N Teeninga","year":"2016","unstructured":"Teeninga N, Guan Z, Stevens J, van Kist- Holthe JE, Ackermans MT, van der Heijden AJ, et al. Population pharmacokinetics of prednisolone in relation to clinical outcome in children with nephrotic syndrome. Ther Drug Monit. 2016;38(4):534\u201345.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"1601_CR34","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/bcp.70103","volume":"91","author":"N Bouazza","year":"2025","unstructured":"Bouazza N, Semeraro M, Lui G, Froelicher-Bournaud L, Choupeaux L, Treluyer JM, et al. Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: analysis of exposure and disease activity. Br J Clin Pharmacol. 2025;91(10):2854\u201364.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1601_CR35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/jps.2600730617","volume":"73","author":"FD Boudinot","year":"1984","unstructured":"Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci. 1984;73(6):774\u201380.","journal-title":"J Pharm Sci"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01601-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01601-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01601-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:47:54Z","timestamp":1770374874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01601-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01601-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alwin D.R. Huitema is an Editorial Board member of Clinical Pharmacokinetics. Alwin D.R. Huitema was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. All other authors declare no (non-)financial or competing interests directly or indirectly related to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing and Financial Interests"}},{"value":"The study was conducted in accordance with the declaration of Helsinki and approved by the medical ethical committee Utrecht (approval numbers: 20-280 and 21-560) for collection of clinical data and blood samples for PK-PD research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All patients gave oral and written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate\/for Publication"}},{"value":"The control stream of the final model was published in Online Resource 3 in the electronic supplementary material.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data, Materials and Code"}},{"value":"JM conducted and coordinated the prospective studies, developed the population PK model and wrote the draft of the manuscript. SE contributed to conduction of one of the prospective studies. AP developed the prednisolone assay and measured all the patients\u2019 samples. CL and MJ were the principal investigators of the studies and supervised on a weekly basis. AdVS supervised development of the PK model on a daily basis. MvL, SN and AH contributed to the manuscript with their expertise on (paediatric) pharmacology, clinical immunology and laboratory. All authors approved the final version of the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}